Word Count: 124
May 25 (SeeNews) - Israeli biotechnology firm Can-Fite Biopharma (TLV:CANF) on Thursday said it has obtained a US patent for a method of treating fatty liver disease with its experimental drug namodenoson.
The patent was granted based onpromising Phase II trial data. The trial assessed the drug in patients with non-alcoholic fatty liver disease, some of whom had developed a more aggressive form known as non-alcoholic steatohepatitis (NASH) that is characterised by liver inflammation and may progress to liver failure.
According to the data, the drug resolved all cases of NASH after 12 weeks of treatment and reduced scarring of the liver and fat accumulation in fatty liver disease and NASH patients.
© 2020. SeeNews. All rights Reserved.